All In Biotech

Drug Trial Radar · NCT07489066

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jul 29, 2028

Study completion Jul 30, 2031

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removable with surgery. The study is seeking participants who: * Are aged 18 years or older * Have either: * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for neoadjuvant therapy, followed by surgical removal of the tumor. Neoadjuvant therapy is a treatment given as a first step to shrink the tumor before surgery. * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for adjuvant therapy and did not achieve a pathological complete response (pCR) from approved treatment that was administered before surgery. Adjuvant therapy is an additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. pCR is defined as absence of viable tumor in all surgically removed samples. * Locally advanced (Stage III) NSCLC that may not be removable with surgery, was treated with concurrent chemoradiotherapy (cCRT), and is a candidate for additional treatment, otherwise known as consolidation therapy. cCRT is chemotherapy and radiation given simultaneously. * Be in good physical condition and have healthy organs based on medical tests. * Do not have known actionable changes in DNA The study has 3 parts and each participant will be assigned to one part by their doctor based on their disease diagnosis: * Part A will test PF-08634404 given with chemotherapy in the neoadjuvant setting, followed by surgery. * Part B will test PF-08634404 alone in adults who already were treated with neoadjuvant chemo-immunotherapy, underwent surgery, and did not achieve pCR per tumor tissue pathology analysis. Neoadjuvant chemo-immunotherapy refers to the combination of chemotherapy with immunotherapy per local standard-of-care, given before surgical removal of the tumor. * Part C will test PF-08634404 alone in adults with unresectable disease who received cCRT and did not have progressive disease. Progressive disease refers to a condition that grows, spreads, or worsens. All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

Conditions

  • Carcinoma
  • Non-Small-Cell Lung
  • Lung Cancer (NSCLC)
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung (NSCLC)
  • Lung Disease
  • Non-Small Cell Lung Cancer
  • Non-small Cell Lung Cancer, Non-squamous
  • Non-small Cell Lung Cancer, Squamous

Interventions

  • PF-08634404Biological

    Concentrate for solution for infusion

  • Chemotherapy Regimen 1Drug

    Injection for intravenous use

  • Chemotherapy Regimen 2Drug

    Injection for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Through 90 days after the last dose of study intervention (Part A only: or 90 days after surgery, whichever is later)
  2. Part A: Surgical Feasibility RateTime frame: Up to approximately 6 months after first dose
  3. Part A: Pathological Complete Response (pCR) rate per International Association for the Study of Lung Cancer (IASLC) guidelines as assessed by central pathology reviewTime frame: Up to approximately 6 months after first dose

Locations

37 sites in 11 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute (Crestwood)

    Huntsville, Alabama · Recruiting

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • Stanford Hospital and Clinics

    Stanford, California · Recruiting

  • Stanford Hospital Investigational Drug Services

    Stanford, California · Recruiting

  • University Cancer & Blood Center, LLC

    Athens, Georgia · Recruiting

  • Hope and Healing Clinical Research

    Hinsdale, Illinois · Recruiting

  • Hope and Healing Clinical Research

    New Lenox, Illinois · Recruiting

  • Nebraska Medicine- Bellevue Medical Center

    Bellevue, Nebraska · Not yet recruiting

  • Cancer Partners of Nebraska

    Lincoln, Nebraska · Recruiting

  • Nebraska Medicine

    Omaha, Nebraska · Not yet recruiting

  • Nebraska Medicine - Village Pointe

    Omaha, Nebraska · Not yet recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Not yet recruiting

  • New Mexico Oncology Hematology Consultants, Ltd

    Albuquerque, New Mexico · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Western Health-Sunshine & Footscray Hospitals

    St Albans, Victoria, Australia · Recruiting

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • LungenClinic Grosshansdorf

    Großhansdorf, Germany · Not yet recruiting

  • Marien Hospital Düsseldorf

    Düsseldorf, North Rhine-Westphalia, Germany · Not yet recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Not yet recruiting

  • Sourasky Medical Center

    Tel Aviv, TELL ABĪB, Israel · Recruiting

  • Casa di Cura Dott. Pederzoli

    Peschiera del Garda, Verona, Italy · Not yet recruiting

  • Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii

    Wroclaw, Poland · Recruiting

  • Pan American Center for Oncology Trials, LLC - Bayamón Office

    Bayamón, Puerto Rico · Recruiting

  • Pan American Center for Oncology Trials, LLC - Manati Office

    Manati, Puerto Rico · Recruiting

  • Pan American Center for Oncology Trials, LLC - Ponce Office

    Ponce, Puerto Rico · Recruiting

  • Hospital Oncologico Dr. Isaac Gonzalez Martinez

    Rio Piedras, Puerto Rico · Recruiting

  • Pan American Center for Oncology Trials, LLC - Ciudadela Office

    San Juan, Puerto Rico · Recruiting

  • Hospital Universitario Puerta de Hierro de Majadahonda

    Majadahonda, Spain · Recruiting

  • Chung Shan Medical University Hospital

    Taichung, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Not yet recruiting

  • Taipei Medical University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.